Johnson & Johnson-owned LifeScan is launching a clinical trial of its OneTouch Verio blood glucose meter to determine whether it can create a greater reduction in A1C levels when used in conjunction with a mobile app.
A post on ClinicalTrials.gov reveals that the company is recruiting 148 patients for a randomized control trial that will compare patients using the OneTouch Verio Flex Blood Glucose Management System alone to patients using it with the LifeScan OneTouch Reveal app. Additionally, the trial will also measure adherence to regular glucose testing, use of the app over 24 weeks, and patient satisfaction.
As part of the study, participants will be receiving text messages from their health provider, encouraging them to take measurements on a regular basis.
The LifeScan’s OneTouch series of glucometers includes the Verio IQ, Verio Pro, and Verio Pro+, which may soon be expanded with the Verio Flex model, which will be used in the clinical trial.
The clinical trial is slated to finish in May 2016.